Newsroom | 5600 results

WATERTOWN, Mass.--(BUSINESS WIRE)--Ingenia Therapeutics, a clinical-stage biotechnology company pioneering next-generation vascular-targeted therapies, announced that the company has received approval from the KRX to proceed with its Initial Public Offering (IPO). The move marks a pivotal transition for the company, supported by a robust pipeline that includes two clinical-stage assets, one of which is IGT-427 (now called MK-8748), an investigational bi-specific antibody (Anti-VEGF/TIE2), for p...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcas...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, on Tuesday, June 9, 2026, at 1:20 p.m. ET. A live webcast of the session will be av...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the “Annual Meeting”) held on May 20, 2026. The detailed results of the vote for the election of directors are set out below: Name For Against Broker Non-Votes Eduardo Alfonso, M.D. 331,573,622 4,244,069 11,452,072 Nathalie Be...

PARIS--(BUSINESS WIRE)--Regulatory News : GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour le traitement des maladies neurodégénératives de la rétine et du système nerveux central, annonce que l’ensemble des 28 résolutions soumises au vote de l’Assemblée Générale Mixte des actionnaires, tenue le 19 mai 2026 et présidée par Laurence Rodriguez, Directrice...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that all 28 resolutions submitted for shareholders’ vote at the Combined Shareholders’ Meeting held on May 19, 2026, and chaired by Laurence Rodriguez, Chief Executive Officer of the Company, were approved....

DULUTH, Ga.--(BUSINESS WIRE)--National Vision Holdings, Inc. (NASDAQ: EYE) (“National Vision” or the “Company”) today announced that the Company is scheduled to present at the William Blair 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 4:00 p.m. Central Time. A live webcast of the presentation will be available in the “Investors” section of the Company’s website at www.ir.nationalvision.com. The webcast will be archived and available on the website shortly after the event....

NEW YORK--(BUSINESS WIRE)--Warby Parker Inc. (NYSE: WRBY), a lifestyle brand focused on vision for all, today unveiled its first Intelligent Eyewear frame designed for all-day, everyday wear. The debut style combines Warby Parker’s distinctive approach to design with Google’s leadership in AI and Samsung’s mobile leadership to create beautifully crafted eyewear that seamlessly enhances everyday life. For more than 16 years, Warby Parker has redefined how consumers shop for glasses by pairing me...

LUGANO, Schweiz--(BUSINESS WIRE)--Da das wissenschaftliche Interesse an lichtbasierter Stimulation, neuroendokriner Regulation und integrativer Medizin international weiter zunimmt, hat das Switzerland Eye Research Institute (SERI Lugano) eine neue internationale wissenschaftliche Outreach-Initiative ins Leben gerufen, die sich auf die Einbindung der Öffentlichkeit und die interdisziplinäre Forschungskommunikation in den Bereichen Neurowissenschaften und zelluläre Modulation konzentriert. Die I...

LUGANO, Svizzera--(BUSINESS WIRE)--Mentre aumenta a livello internazionale l'interesse scientifico per la stimolazione basata sulla luce, la regolazione neuroendocrina e la medicina integrativa, lo Switzerland Eye Research Institute (SERI Lugano) ha lanciato una nuova iniziativa scientifica internazionale incentrata sul coinvolgimento del pubblico e sulla comunicazione interdisciplinare nel settore delle neuroscienze e della modulazione cellulare. L'iniziativa mira a promuovere la più ampia com...